Biomarkers for advancing diagnosis and prognosis in stroke

The complexity and incomplete understanding of the pathophysiology of stroke poses substantial challenges to personalised medicine and the development of novel therapies, as reflected in the neutral results of many randomised trials. Current clinical algorithms lack the precision to diagnose stroke before hospital admission, predict disease progression and recovery, or assess recurrence risk. Biomarkers are urgently needed, yet the absence of a robust evidence base hinders their clinical translation. To lay the groundwork for addressing this knowledge gap, an international multidisciplinary panel of stroke experts conducted a literature review that informed a Delphi consensus process. The stroke experts panel…

• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• AP
  Alnylam Pharmaceuticals
• CB
  CSL Behring
• UK
  United Kingdom Clinical Research Collaboration
• UO
  University of Cambridge
• NN
  Novo Nordisk
• MD
  Ministerio de Ciencia e Innovación